Silexion Therapeutics Reports $6.3 Million Net Loss and Progress in Clinical Trials

Silexion Therapeutics Corp reported significant financial developments in its latest quarterly filing, revealing a net loss of $6.3 million for the six months ending June 30, 2026, compared to a loss of $4.2 million during the same period in 2025. The company's total operating expenses surged to $6.4 million, up from $3.9 million year-over-year, primarily driven by increased research and development costs associated with the preparation for its Phase 2/3 clinical trial of SIL204, a therapy targeting KRAS-driven cancers. The increase in research and development expenses was particularly notable, rising by 125% to $3.6 million, largely due to higher subcontractor and consultant costs.

In terms of liquidity, Silexion's cash and cash equivalents decreased to $2.2 million as of June 30, 2026, down from $6.1 million at the beginning of the year. The company reported negative cash flows from operating activities of $6.6 million for the first half of 2026, reflecting its ongoing reliance on financing to support operations. The company has been actively raising capital through various means, including public offerings and an at-the-market (ATM) facility, which has allowed it to raise approximately $1.9 million in the second quarter of 2026.

Strategically, Silexion has made significant progress in its clinical development, receiving regulatory approvals from both the Israeli Ministry of Health and Germany's Federal Institute for Drugs and Medical Devices to initiate its clinical trial for SIL204. The trial commenced in July 2026 at the Tel Aviv Sourasky Medical Center, with plans to expand to additional sites in Israel and Germany. This marks a critical step in the company's efforts to advance its lead product candidate, which aims to address a significant unmet medical need in treating KRAS-driven cancers.

The company has also undergone organizational changes, including the establishment of a new subsidiary, Silexion Therapeutics GmbH, to facilitate clinical trials in Germany. Additionally, Silexion has increased its authorized share capital to support ongoing financing activities, which is crucial for maintaining compliance with Nasdaq listing requirements. As of June 30, 2026, the company had restored its shareholders' equity above the $2.5 million threshold required for continued listing on the Nasdaq Capital Market.

Looking ahead, Silexion anticipates continued operating losses as it invests in the development of SIL204 and other potential product candidates. The company acknowledges the need for additional capital to fund its operations and has expressed substantial doubt about its ability to continue as a going concern without further financing. Management is actively exploring various funding options to ensure the sustainability of its operations and the advancement of its clinical programs.